Alexandria Real Estate Equities Inc - Company Profile
Powered by 
All the sales intelligence you need on Alexandria Real Estate Equities Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Alexandria Real Estate Equities Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Alexandria Real Estate Equities Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Alexandria Real Estate Equities Inc (Alexandria) is a real estate investment trust (REIT). The company's primary activities include owning, operating, developing, acquisition, and redevelopment of properties and offers them on lease. Alexandria provides rentable properties, cluster, and incubators for life science industry. It serves multinational pharmaceutical companies, biotechnology firms, digital health and agtech companies, to academic and medical research institutions, the US government research agencies, and venture capital firms. The company has an operational presence in San Francisco, Greater Boston, San Diego, New York City, Maryland, Seattle, and Research Triangle Park, in the US. Alexandria is headquartered in Pasadena, California, the US.
Headquarters
United States of America
Address
26 North Euclid Avenue, Pasadena, California, 91101
Website
www.are.com
Telephone
1 626 5780777
No of Employees
514
Industry
Construction
Ticker Symbol & Exchange
ARE (NYSE)
Revenue (2024)
$3.0B
-6%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-542.7%
(2024 vs 2023)
Market Cap*
$8.5B
Net Profit Margin (2024)
XYZ
-570.9%
(2024 vs 2023)
* As of and is in US$
Alexandria Real Estate Equities Inc premium industry data and analytics
Products and Services
| Services |
|---|
| Acquisition |
| Development |
| Maintenance |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In January, the company received approval from the city of Bellevue to build a seven-story residential building west of the Spring District in Bellevue, Washington, the US. |
| 2025 | Corporate Changes/Expansions | In September, the company and Eli Lilly opened Lilly Gateway Labs San Diego at the One Alexandria Square Megacampus in Torrey Pines to support early-stage biotech innovation. |
| 2025 | Contracts/Agreements | In July, the company signed its largest-ever life science lease: a 16-year deal with a longtime multinational pharma tenant for a 466,598 RSF (Rentable Square Feet) build-to-suit R&D hub at Campus Point in San Diego. |
Competitor Comparison
| Key Parameters | Alexandria Real Estate Equities Inc | Jones Lang LaSalle Inc | Ventas Inc | BXP Inc | Healthpeak Properties Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Pasadena | Chicago | Chicago | Boston | Denver |
| State/Province | California | Illinois | Illinois | Massachusetts | Colorado |
| No. of Employees | 514 | 113,200 | 542 | 714 | 411 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Joel S Marcus | Chairman | Executive Board | - | 78 |
| Peter M. Moglia | Chief Investment Officer; Chief Executive Officer | Senior Management | 2023 | 59 |
| Marc E. Binda | Treasurer; Chief Financial Officer | Senior Management | 2023 | 50 |
| Andres R. Gavinet | Chief Accounting Officer | Senior Management | 2012 | 57 |
| Lawrence J Diamond | Regional Market Director-Maryland; Co-Chief Operating Officer | Senior Management | 2018 | 67 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer